Concepedia

Author

Angelo Rosolen

University of Padua

Also Known As

A Rosolen, ANGELO ROSOLEN, Angelo Rosolen, Angelo Rosolen (84555), Georg Mann, Non -Hodgkin's Lymphoma, Rosolen Angelo

174

Publications

4.4K

Citations

40

H-Index

84

Concepts

All Affiliations

University of PaduaAzienda Ospedale - Università PadovaIstituto Giannina GasliniIstituti di Ricovero e Cura a Carattere ScientificoCittà della Speranza Foundation
AR

About

Angelo Rosolen is an author at University of Padua specializing in medicine, pathology, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

20

23

1.3K

2

Health Sciences

3

3

109

3

Natural Sciences

2

2

190

4

Engineering

1

1

48

5

Allergy

1

1

51

Angelo Rosolen

×

63

Publications

3.7K

Citations

38

H-Index

YearCitations

Revised International Pediatric Non-Hodgkin Lymphoma Staging System

Angelo Rosolen, Sherrie L. Perkins, CR Pinkerton,

Journal of Clinical Oncology

2015

226

Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group

Laurence Brugières, Marie‐Cécile Le Deley, Angelo Rosolen,

Journal of Clinical Oncology

2009

215

Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial

Marie‐Cécile Le Deley, Angelo Rosolen, Denise Williams,

Journal of Clinical Oncology

2010

197

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Gianni Bisogno, Meriel Jenney, Christophe Bergeron,

The Lancet Oncology

2018

182

Identification of Ellagic Acid as Potent Inhibitor of Protein Kinase CK2:  A Successful Example of a Virtual Screening Application

Giorgio Cozza, Paolo Bonvini, Elisa Zorzi,

Journal of Medicinal Chemistry

2006

150

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.

Paolo Bonvini, T. Gastaldi, Brunangelo Falini,

PubMed

2002

131

Primitive Myxoid Mesenchymal Tumor of Infancy

Rita Alaggio, Vito Ninfo, Angelo Rosolen,

The American Journal of Surgical Pathology

2006

99

microRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas

Christof Schneider, Manu Setty, Antony B. Holmes,

Proceedings of the National Academy of Sciences

2014

94

Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma

Eva Landmann, Birgit Burkhardt, Martin Zimmermann,

Haematologica

2017

94

Ubiquitination and Proteasomal Degradation of Nucleophosmin-Anaplastic Lymphoma Kinase Induced by 17-Allylamino-Demethoxygeldanamycin

Paolo Bonvini, Henry Dalla Rosa, Nadia Vignes,

Cancer Research

2004

92

Page 1